Rapid Formation of Novel Targeted Prodrugs: Based on validated active substances and targets, the platform can quickly generate novel targeted prodrugs that offer significant improvements in pharmacokinetics/pharmacodynamics or safety. It efficiently produces candidate compounds with high clinical development value.

High druggability with robust patent protection to enable accelerated development cycles, reduced costs, and sustained competitive advantage.

Effective chemical structure modifications are used to improve various drug properties, including physicochemical characteristics, delivery and transport efficiency, enzyme selectivity, and compound stability. AI technology is employed to enhance precision and efficiency.

The platform achieves targeted delivery to specific disease-affected organs. This not only ensures therapeutic efficacy but also provides better safety profiles, achieving an optimal balance between efficacy and safety.

Capable of novel sequence design and modification of both oligonucleotides drugs and messenger RNA drugs.

An innovative chemical modification technology platform that can be applied toward differentiated design for target organs and improved PK/PD, efficacy and overall druggability of RNA therapeutics/oligonucleotides drugs.

Diversified advanced drug delivery technology, capable of selectively delivering drugs for liver and extrahepatic organs as well as systemic or local drug delivery mechanisms.